155 related articles for article (PubMed ID: 38391239)
1. Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.
Bestvina CM; Waters D; Morrison L; Emond B; Lafeuille MH; Hilts A; Lefebvre P; He A; Vanderpoel J
J Med Econ; 2024; 27(1):292-303. PubMed ID: 38391239
[TBL] [Abstract][Full Text] [Related]
2. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer.
Vanderpoel J; Stevens AL; Emond B; Lafeuille MH; Hilts A; Lefebvre P; Morrison L
J Med Econ; 2022; 25(1):457-468. PubMed ID: 35289703
[TBL] [Abstract][Full Text] [Related]
3. Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices.
Sheffield BS; Eaton K; Emond B; Lafeuille MH; Hilts A; Lefebvre P; Morrison L; Stevens AL; Ewara EM; Cheema P
Curr Oncol; 2023 Feb; 30(2):2348-2365. PubMed ID: 36826141
[TBL] [Abstract][Full Text] [Related]
4. Value of next generation sequencing (NGS) testing in advanced cancer patients.
Ortendahl JD; Cuyun Carter G; Thakkar SG; Bognar K; Hall DW; Abdou Y
J Med Econ; 2024; 27(1):519-530. PubMed ID: 38466204
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing-Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non-Small-Cell Lung Cancer in the United States.
Zou D; Ye W; Hess LM; Bhandari NR; Ale-Ali A; Foster J; Quon P; Harris M
J Mol Diagn; 2022 Aug; 24(8):901-914. PubMed ID: 35688357
[TBL] [Abstract][Full Text] [Related]
6. Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model.
Pennell NA; Mutebi A; Zhou ZY; Ricculli ML; Tang W; Wang H; Guerin A; Arnhart T; Dalal A; Sasane M; Wu KY; Culver KW; Otterson GA
JCO Precis Oncol; 2019 Dec; 3():1-9. PubMed ID: 35100695
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review.
Zheng Y; Vioix H; Liu FX; Singh B; Sharma S; Sharda D
Future Oncol; 2022 Feb; 18(4):505-518. PubMed ID: 34865516
[TBL] [Abstract][Full Text] [Related]
8. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
9. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
10. Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non-Small-Cell Lung Cancer in the United States.
Lemmon CA; Zhou J; Hobbs B; Pennell NA
JCO Precis Oncol; 2023 Jan; 7():e2200294. PubMed ID: 36634300
[TBL] [Abstract][Full Text] [Related]
11. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
Dalal AA; Guerin A; Mutebi A; Culver KW
J Med Econ; 2018 Jul; 21(7):649-655. PubMed ID: 29516752
[TBL] [Abstract][Full Text] [Related]
12. Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.
Stenzinger A; Cuffel B; Paracha N; Vail E; Garcia-Foncillas J; Goodman C; Lassen U; Vassal G; Sullivan SD
Oncologist; 2023 May; 28(5):e242-e253. PubMed ID: 36961477
[TBL] [Abstract][Full Text] [Related]
13. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective.
de Alava E; Pareja MJ; Carcedo D; Arrabal N; García JF; Bernabé-Caro R
Expert Rev Pharmacoecon Outcomes Res; 2022 Sep; 22(6):1033-1042. PubMed ID: 35593180
[TBL] [Abstract][Full Text] [Related]
15. Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a
Cai B; Zhou ZY; Xue W; Hazra NC; Singh M; Mishra D; Brixner D; Oderda G; Biskupiak J
J Med Econ; 2021; 24(1):131-139. PubMed ID: 33397178
[TBL] [Abstract][Full Text] [Related]
16. Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer.
Yu TM; Morrison C; Gold EJ; Tradonsky A; Arnold RJG
Value Health; 2018 Nov; 21(11):1278-1285. PubMed ID: 30442274
[TBL] [Abstract][Full Text] [Related]
17. Budget impact analysis of next-generation sequencing versus sequential single-gene testing in Japanese patients with advanced non-small-cell lung cancer.
Matsuda H; Ogawa T; Sadatsuki Y; Tsujino T; Wada S; Kim SW; Hatanaka Y
Respir Investig; 2023 Jan; 61(1):61-73. PubMed ID: 36460584
[TBL] [Abstract][Full Text] [Related]
18. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.
He C; Wei C; Wen J; Chen S; Chen L; Wu Y; Shen Y; Bai H; Zhang Y; Chen X; Li X
J Cancer Res Clin Oncol; 2022 Feb; 148(2):321-330. PubMed ID: 34693477
[TBL] [Abstract][Full Text] [Related]
20. Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
Schwartzberg L; Daniel D; Vaena D; Slater D; Staszewski H; Fang B; Seneviratne L; Yu E; Price R; Szado T; Meyer CS; Shah A; Ma E
Future Oncol; 2023 Jun; 19(20):1397-1414. PubMed ID: 37318757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]